0
Deep & Emerging Tech·October 29, 2026·1 min read

Lilly raises outlook for third time this year as Zepbound sales soar

Share

Three outlook raises in a year off Zepbound shows GLP-1s are becoming a core revenue pillar, not a side bet. Employers, payers, and adjacent health-tech startups should plan for weight-loss drugs as a structural line item and design services around adherence, side-effect monitoring, and long-term metabolic care.